Electrosprayed hierarchical mesoporous Mn0.5Ti2(PO4)3@C microspheres as promising High-Performance anode for Potassium-Ion batteries.

NASICON-structured Ti-based polyanion compounds benefit from a stable structural framework, large ion channels, and fast ion mobility. However, the large radius of potassium and its poor electronic conductivity restrict its use in potassium-ion batteries. Herein, hierarchical mesoporous Mn0.5Ti2(PO4)3@C microspheres have been successfully synthesized using a simple electrospraying method. These microspheres consist of Mn0.5Ti2(PO4)3 nanoparticles evenly embedded in three-dimensional mesoporous carbon microspheres. The hierarchical mesoporous micro/nanostructure facilitates the rapid insertion and extraction of K+, while the three-dimensional carbon microspheres matrix enhances electrical conductivity and prevents active materials from collapsing during cycling. So the hierarchical mesoporous Mn0.5Ti2(PO4)3@C microspheres exhibit a high reversible discharge specific capacity (306 mA h g-1 at 20 mA g-1), a notable rate capability (123 mA h g-1 at 5000 mA g-1), and exceptional cycle performance (148 mA h g-1 at 500 mA g-1 after 1000 cycles). The results show that electrosprayed Mn0.5Ti2(PO4)3@C microspheres are a promising anode for PIBs.

ß-1,3-d-glucan particles-based "nest" protected co-loaded Rhein and Emodin regulates microbiota and intestinal immunity for ulcerative colitis treatment.

Herein, a ß-1,3-D-glucan based yeast cell wall loaded with co-loaded nanoparticles of Rhein (RH) and Emodin (EMO), was developed for the combined treatment of ulcerative colitis (UC) by modulating gut microbiota and the Th17/Treg cell balance. This was achieved through an oral "nano-in-micro" advanced drug delivery system. Specifically, RH was grafted onto the HA chain via disulfide bonds to synthesize a reduction-sensitive carrier material and then used to encapsulate EMO to form nanoparticles with a specific drug ratio (denoted as HA-RH/EMO NPs). As anticipated, HA-RH/EMO NPs were encased within the "nests"-yeast cell wall microparticles (YPs), efficiently reach the colon and then released gradually, this occurs mainly due to the degradation of ß-1,3-D-glucan by ß-glucanase. Additionally, HA-RH/EMO NPs demonstrated a significant reduction-sensitive effect in GSH stimulation evaluations and a remarkable ability to target macrophages in in vitro cell uptake studies. Notably, HA-RH/EMO NYPs reduced inflammatory responses by inhibiting the PI3K/Akt signaling pathway. Even more crucially, the oral delivery and drug combination methods significantly enhanced the regulatory effects of HA-RH/EMO NYPs on gut microbiota and the Th17/Treg balance. Overall, this research marks the first use of YPs to encapsulate two components, RH and EMO, presenting a promising therapeutic strategy for UC.